Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 3Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Virus Diseases 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Graft vs Host Disease 1

Interventions

Stem Cell Transplantation 3pertuzumab 2entrectinib 2cobimetinib 2capmatinib 2alectinib 2Vemurafenib 2Trastuzumab 2Cyclophosphamide 2trametinib 1thymoglobulin 1peginterferon alfa-2b 1orelabrutinib 1luspatercept 1kalinox 1dabrafenib 1atezolizumab 1Trimethoprim, Sulfamethoxazole Drug Combination 1Tretinoin 1Standard of Care 1Practice Guidelines as Topic 1Patient Comfort 1Palliative Care 1Melphalan 1Immunotherapy, Adoptive 1Immunoglobulins 1Imipenem 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Ferric Oxide, Saccharated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Hematologic Neoplasms × thymoglobulin × Clear all
NCT03818334 2019-02-01

Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies

Hospital Israelita Albert Einstein

Phase 2/3 Recruiting
50 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Virus Diseases, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡